Literature DB >> 17468115

Acquired resistance to echinocandins in Candida albicans: case report and review.

Marie-Thérèse Baixench1, Naji Aoun, Marie Desnos-Ollivier, Dea Garcia-Hermoso, Stéphane Bretagne, Sandrine Ramires, Christophe Piketty, Eric Dannaoui.   

Abstract

OBJECTIVES: A patient with Candida albicans thrush and oesophagitis was treated with high doses of caspofungin but treatment eventually failed. Four C. albicans isolates were serially recovered before and after caspofungin treatment. A microbiological study was performed to characterize these four isolates.
METHODS: In vitro antifungal susceptibility testing was performed by the EUCAST reference method in RPMI and AM3 and by Etest. Molecular typing of the four isolates was done by sizing three polymorphic microsatellite markers. To look for specific mutations, sequencing of a region of the gene encoding the 1-3-beta-D-glucan synthase was performed for the four isolates.
RESULTS: In vitro antifungal susceptibility testing showed an increase in both caspofungin and micafungin MICs for the two isolates recovered after caspofungin treatment failure. The best discrimination between the pre-treatment and post-treatment isolates was obtained with Etest. Molecular typing of the four isolates showed that the post-treatment isolates with reduced susceptibility were identical to a susceptible pre-treatment isolate, suggesting the acquisition of caspofungin resistance. Sequencing of the gene encoding the 1-3-beta-D-glucan synthase showed a mutation responsible for an amino acid change at Phe-641 that could confer reduced susceptibility to both echinocandins.
CONCLUSIONS: Our results indicate that is it useful to perform in vitro susceptibility testing in the cases of clinical failure during caspofungin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468115     DOI: 10.1093/jac/dkm095

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  65 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  Antifungal therapy for newborn infants with invasive fungal infection.

Authors:  Linda Clerihew; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

3.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

5.  Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Authors:  Marie Desnos-Ollivier; Olivier Moquet; Taieb Chouaki; Anne-Marie Guérin; Françoise Dromer
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

6.  Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.

Authors:  Ana Alastruey-Izquierdo; Alicia Gómez-López; Maiken C Arendrup; Cornelia Lass-Florl; William W Hope; David S Perlin; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

7.  Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.

Authors:  E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.

Authors:  Mohamed Khlif; Hervé Bogreau; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

9.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

Review 10.  Activation of stress signalling pathways enhances tolerance of fungi to chemical fungicides and antifungal proteins.

Authors:  Brigitte M E Hayes; Marilyn A Anderson; Ana Traven; Nicole L van der Weerden; Mark R Bleackley
Journal:  Cell Mol Life Sci       Date:  2014-02-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.